Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MGAM | O43451 | 2/20 | 0.60 |
| ▸ | SI | P14410 | 2/20 | 0.60 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.60 |
| ▸ | DHODH | Q02127 | 2/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16742020 | 1.00 | GUSB (0.64) | GUSBGAAMAPTRAB9AMAPK1 | |
| SCHEMBL16742058 | 0.88 | GUSB (0.64) | GUSBGAAMAPTRAB9ANPC1 | |
| SCHEMBL16742057 | 0.88 | GUSB (0.64) | GUSBGAAMAPTRAB9ANPC1 | |
| SCHEMBL17150984 | 0.83 | MAPT (0.76) | GUSBGAAMAPTRAB9AMAPK1 | |
| SCHEMBL18980779 | 0.83 | MAPT (0.76) | GUSBGAAMAPTRAB9AMAPK1 | |
| SCHEMBL18980780 | 0.83 | MAPT (0.76) | GUSBGAAMAPTRAB9AMAPK1 | |
| SCHEMBL28451541 | 0.76 | GAA (0.58) | GUSBGAAMAPTRAB9AMAPK1 | |
| SCHEMBL25613885 | 0.76 | GAA (0.72) | GUSBGAAMAPTRAB9AMAPK1 | |
| SCHEMBL25613862 | 0.76 | GUSB (0.67) | GUSBGAAMAPTRAB9ANPC1 | |
| SCHEMBL19631414 | 0.75 | DHODH (0.95) | GAAMAPTRAB9AMAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| EP-3071199-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Genzyme Corporation (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015077535-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | GUSB 1002/4885GAA 167/4885MAPT 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.